Affimed Provides Update on ASCO AFM13-104 Oral Presentation
06 mai 2022 16h02 HE
|
Affimed N.V.
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
CORRECTING and REPLACING -- Affimed N.V.
27 avr. 2022 17h21 HE
|
Affimed N.V.
In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American...
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)
27 avr. 2022 16h05 HE
|
Affimed N.V.
A presentation on the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13, in patients with CD30-positive lymphomas will be given in an...
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 avr. 2022 11h28 HE
|
Affimed N.V.
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their...
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
12 avr. 2022 22h02 HE
|
Affimed N.V.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Proposed Public Offering of Common Shares
12 avr. 2022 16h03 HE
|
Affimed N.V.
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
10 avr. 2022 12h05 HE
|
Affimed N.V.
100% objective response rate and improvement in the rate of complete responses (CR) from 38% to 62% after a second cycle in 13 patients treated at the recommended phase 2 dose (RP2D)Patients enrolled...
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors
08 avr. 2022 13h23 HE
|
Affimed N.V.
The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of 160 mg and higherThe maximum tolerated dose...
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
31 mars 2022 06h30 HE
|
Affimed N.V.
Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022Presented interim data in December 2021 of the combination study of AFM13...
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022
24 mars 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...